Salt Composition in both
Medroxyprogesterone acetate 150mg
Salt Composition
(same for both)
You Searched
We only sell the best substitute from top brands
Our Recommendation
Depo Provera 150mg Injection 1ml
Vial of 1 ml
330+ Customers trust this
WHO GMP Certified
Doctor ApprovedMedicine Comparison
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
Pantosec DSR 30/40mg PR Capsule 10sPantosec 40mg Tablet 10sCipvildin M 500/50mg Tablet 15sAb Rozu 10mg Tablet 10sCipcal D3 60000IU Capsule 4sCipcal 500mg/250IU Tablet 15sDapaquest 10mg Tablet 10sMontecip LC 5/10mg Tablet 10sLipvas 10mg Tablet 10sParacip 650mg Tablet 10sView More
Aerolife inhalation Device 1sAir Space Wit Exhle Valve Device 1sBp Monitor (Omron) Hem 8712 Device 1sContour Plus System 1sDigital Thermometer Mercury Device 1sDuohaler DPI Device 1sIbreathe DPI Inhealer Device 1sMachaler DPI Device 1sMacspacer Device 1sNovopen 4 | Diabetes Monitoring Devices 1s
Yes NOUnisuro Rehabilitation ProgramPerformance of ProgramProgram
No FeaturedEvaluating the effectiveness of treatment
Disclaimer:Medroxyprogesterone acetate 150mg is a prescription medication and may beacyclovir. Please consult your doctor before using this medication. The content on this page has been supplied to can provide specific guidance. Please note that individual results may vary. Any specific results, adverse events, clinical data, or other information provided in this page are merely general information about the medication and may not indicate a specific dosage form. We only provide specific information about the medication and does not take it as a given. If you have any questions or concerns about this medication, please consult your doctor. This information is not intended to diagnose, treat, cure, or prevent any disease or health issue. This page serves as a summary of the information we provide to help you understand the medication, its dosage, and any potential side effects. If you have any questions or concerns about this information, please consult your doctor. Any specific results results, adverse events, clinical data, or other information provided in this page are merely general information about the medication and may not indicate a specific dosage form.
Top brands of medroxyprogesterone acetate 150mg include:
• Zomig India Ltd.
• Sun Pharma Ltd.
Depo-Provera, or medroxyprogesterone, is a progestin-only contraceptive used for the prevention of pregnancy.
It is FDA-approved to prevent pregnancy in women who are at risk for developing a type of endometriosis. It is also used for the treatment of heavy periods.
Depo-Provera works by preventing ovulation (the release of an egg from an ovary) and thickening the cervical mucus. The thickening of the mucus causes a fall in blood pressure.
If you are at risk for having a pregnancy due to a type of endometriosis, then you may need to see a doctor for a prescription birth control method. Depo-Provera is also sometimes used to prevent the birth of a child.
Depo-Provera is often used to prevent pregnancy, but this does not always require a prescription.
The medicine is also sometimes used to prevent pregnancy in women with:
hirsute menstruation
pregnant
a heavy period
caused by irregular bleeding
a woman who has had a stroke
a bleeding disorder
a uterus with a strong fall in blood pressure
a blood disorder that does not go away, so that the doctor does not know whether it is related to endometriosis.
Depo-Provera works by preventing ovulation in women who are at risk of developing a type of endometriosis. It does this by blocking the hormone called progesterone, which can cause the ovaries to produce less estrogen, which can be harmful to the lining of the uterus.
The hormone progesterone is also an important part of the lining of the uterus that makes the endometrial lining thick. It can interfere with the lining’s ability to make an egg.
A woman who has had a hysterectomy for a uterus can also experience an increase in the number of endometrial adnexa, which are thin lining cells that are normally located in the uterus, in addition to the endometrium.
Depo-Provera is a very effective contraceptive method used to prevent pregnancy. The two main methods are Depo-Provera and the contraceptive pill, Depo-SubQ Provera.
Depo-SubQ Provera is the only birth control method FDA-approved by the FDA. It is the first of the three methods.
The method of birth control known as the copper-pill method is more effective for many women with a uterus. But it does not have any birth control method.
If you are considering using Depo-Provera or another birth control method, you must consult with a licensed healthcare provider to determine if it is right for you.
Objective:To evaluate the efficacy of a daily intrauterine device-based treatment program for women with epilepsy and to compare it with the efficacy of a monthly regimen for women with epilepsy.
Methods:A prospective, randomized, double-blind study was conducted in a randomized, parallel-group, placebo-controlled, double-blind, phase 2 trial of a single intrauterine device-based treatment program for women with epilepsy. The trial included women who were in their early 20s or greater and had epilepsy or were taking a daily anticonvulsant medication for an extended period. Women were randomized to one of two treatment regimens for either an intermittent (1.5 mg/month) or daily (2.5 mg/month) intraparenchymal therapy for 2 years or the continuous (4.5 mg/month) intraparenchymal therapy for 1 year. The trial was completed after the first dose of each treatment, at 6 months, with the first dose of each treatment for 3 months. The primary outcome was seizure-free days. Secondary outcomes included the percentage of women who were seizure free, time from initial treatment to seizure seizure, and percentage of women who had seizure-free days over the first year of therapy. The secondary outcomes included the percentage of women who had received seizure-free medications, length of seizure control, and overall seizure occurrence.
Results:The study was a 6-month, single-center, randomized, double-blind, parallel-group, placebo-controlled, double-blind, phase 2 trial. After treatment initiation, a 1-year course of treatment with intermittent or daily intrauterine device-based treatment was the most commonly used treatment method, followed by continuous intraparenchymal therapy, and the continuous intraparenchymal therapy for 1 year. For the continuous intraparenchymal therapy, the incidence of seizure-free days was 6.5% at 6 months and 9.6% at 1 year. For the intermittent or daily treatment, the average percentage of seizure-free days was 1.2% at 6 months and 1.2% at 1 year. The incidence of seizure-free days was lower in women who received a continuous intraparenchymal therapy versus those who did not. The average percentage of time from initial treatment to seizure seizure was 2.6 months at 6 months and 2.8 months at 1 year. For the continuous intraparenchymal therapy, the incidence of seizure-free days was 6.8% at 6 months and 8.2% at 1 year. For the intermittent or daily therapy, the average percentage of time from initial treatment to seizure seizure was 2.1 months at 6 months and 2.7 months at 1 year. There were no significant differences in seizure-free days between the continuous intraparenchymal therapy and the intermittent or daily therapy. The primary end points were seizure-free days (4.5% vs. 1.2%) and overall seizure occurrence (6.7% vs. 3.4%).
Conclusions:Although the effect of the continuous intraparenchymal therapy was similar to that of the intermittent or daily therapy, the average percentage of seizure-free days was lower in women who were receiving a continuous intraparenchymal therapy versus those who did not. The continuous intraparenchymal therapy may be more effective than the intermittent or daily therapy at treating epilepsy.
Keywords: intraparenchymal, seizure, treatment, seizure, pregnancy, pregnancy category, long term, pregnancy, seizure, pregnancy categoryMETHODS
The study was conducted in accordance with the Declaration of Helsinki, and was approved by the institutional review board of the University of Texas Health Science Center at San Antonio (IRB number # R15-022-08-0).
Sixty-eight women with epilepsy (age 18–45 years) with at least one pregnancy were included in the study. They were randomly assigned to receive the intraparenchymal therapy (n = 34) or the continuous intraparenchymal therapy (n = 34). Patients were instructed to receive the intraparenchymal therapy for 5–10 weeks after their first dose. Secondary outcomes included the percentage of women who were seizure free, time from initial treatment to seizure seizure, and time from initial treatment to seizure seizure.
When a man is diagnosed with an ovarian cancer, he may receive the same or slightly different medication as a woman with an ovary cancer. This is known as a “post-cancer” medication, and it may be used to prevent the recurrence of an ovarian cancer or to treat other conditions.
The drug Depo-Provera (medroxyprogesterone acetate) is a synthetic hormone that mimics the action of the natural hormone progesterone. In a study of more than 3,300 women with cancer of the ovary and breast, researchers found that men who had an ovarian tumor with no other cancer were more likely to have a recurrence than those who had a cancer with a hormone-related tumor (a “prognosis”).
A study of more than 2,400 patients with ovarian cancer found that patients with cancer with an ovarian tumor had a higher risk of recurrence than those with a hormone-related tumor (a “prognosis”).
The researchers also compared the risk of recurrence with that of a hormone-related tumor. The researchers found that men with an ovarian tumor who had not had a tumor that had been removed were more likely to have a recurrence than men who had a tumor removed with the hormone-related tumor.
“It’s a bit unusual to hear that men with a hormone-related tumor and a pro-oestrogen-sensitive ovarian cancer receive a recurrence,” Dr. Nader H. Abdo, a urologist at Memorial Sloan Kettering Cancer Center, toldThe New York Times.
The study was funded by the U. S. National Institutes of Health and was published in the journalNeurology, the journal of theAmerican Journal of Medicine
Abdo and his colleagues conducted a study to evaluate the risk of a recurrence in women with ovarian cancer who received a hormonal-related tumor and a hormone-sensitive ovarian cancer.
A total of 12,600 patients who had a recurrence at diagnosis of a hormone-sensitive ovarian tumor and a hormone-related ovarian cancer were enrolled in the study. They received an intracerebral injection of medroxyprogesterone acetate (Depo-Provera).
They received a total of 4,400 days of treatment to prevent the recurrence of the cancer. After 4 years, the patients who received the combined hormone- and progestin-based treatment had a significantly higher risk of a recurrence (2.2 times that of a hormone-sensitive cancer).
The researchers used a prognostic model to predict the risk of recurrence in women who received a combined hormonal and progestin-based treatment.
They determined that there was no difference in the risk of recurrence between women who received an intracerebral injection of medroxyprogesterone acetate and a control group of women who received a combined hormonal and progestin-based treatment.
The study was published in the journal, and was published in the July 15, 2013 issue of theAnnals of Internal Medicine
Abdo and his team found that women who received the combined hormonal and progestin-based treatment had a significantly higher risk of a recurrence than women who received only the hormone- and progestin-based treatment.
A comparison of their risk of recurrence with that of a hormone-related tumor found that the risk of recurrence was 2.2 times that of a hormone-related tumor.
“The findings are interesting because they show that men with a hormone-sensitive ovarian cancer who received the combined hormonal and progestin-based treatment were more likely to have a recurrence than men who had a tumor removed with the hormone-related tumor,” the study authors wrote.
“This finding is surprising because a hormone-sensitive ovarian cancer does not cause cancer in the ovary and breast. It does cause cancer in the ovary and breast in men.
“But if a man with a hormone-sensitive ovarian cancer had a recurrence with no other cancer, he would have been at a higher risk of recurrence than the men who received a hormone- and progestin-based treatment.”
Stade de France Pharmacy